真实世界研究:抗VEGF、地塞米松或激光治疗视网膜分支静脉阻塞性黄斑水肿的5661例患者证据
该研究基于2002年2月至2017年9月27家NHS信托机构收集的常规诊疗数据,纳入5661例初治、单一治疗模式的视网膜分支静脉阻塞继发黄斑水肿患者,比较抗VEGF、玻璃体腔地塞米松和黄斑激光的视力变化与治疗次数。结果显示抗VEGF组视力改善更高且更持久,但治疗负担更重。
要点
- 抗VEGF组12个月视力平均提升9.6个字母,高于地塞米松的4.5和激光的0.9。
- 18个月时抗VEGF组视力提升9.5个字母,地塞米松组提升3.0,激光组下降1.5。
- 抗VEGF组12个月平均治疗5.1次,36个月平均10.3次,治疗负担高于其他组。
核心结论
- 抗VEGF治疗视网膜分支静脉阻塞继发黄斑水肿的视力改善高于地塞米松和黄斑激光,且更持久。
- 抗VEGF治疗负担更重,但36个月内治疗次数有所减少。
- 基线视力优于临床试验患者的人群中,抗VEGF和地塞米松均能维持较高视力水平。
研究设计与样本
- 基于27家NHS信托机构2002年2月至2017年9月常规诊疗数据的真实世界研究。
- 纳入5661例初治、单一治疗模式、无白内障手术史的视网膜分支静脉阻塞继发黄斑水肿患者。
- 比较抗VEGF、玻璃体腔地塞米松和黄斑激光三组的治疗次数及视力较基线变化,随访至3年。
主要发现
- 基线视力:抗VEGF组57.1字母,地塞米松组53.1字母,激光组62.3字母。
- 12个月视力变化:抗VEGF组66.72(+9.6),地塞米松组57.6(+4.5),激光组63.2(+0.9)。
- 18个月视力变化:抗VEGF组66.6(+9.5),地塞米松组56.1(+3.0),激光组60.8(-1.5)。
- 抗VEGF组36个月视力68.0(+10.9)。
- 12个月平均治疗次数:抗VEGF组5.1,地塞米松组1.5,激光组1.2;18个月分别为5.9、1.7、1.2;抗VEGF组36个月为10.3。
临床怎么用
- 真实世界数据支持抗VEGF作为视网膜分支静脉阻塞继发黄斑水肿的首选治疗以获取更优且更持久的视力改善。
- 选择地塞米松时需权衡其较低治疗次数与较小视力增益。
- 抗VEGF治疗需向患者说明较高的注射负担,但长期治疗次数可能减少。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Clinical trials suggest anti-vascular endothelial growth factor is more effective than intravitreal dexamethasone as treatment for macular oedema secondary to branch retinal vein occlusion. This study asks if 'real world' data from a larger and more diverse population, followed for a longer period, also support this conclusion. METHODS: Data collected to support routine care at 27 NHS (National Health Service) Trusts between February 2002 and September 2017 contained 5661 treatment-naive patients with a single mode of treatment for macular oedema secondary to branch retinal vein occlusion and no history of cataract surgery either during or recently preceding the treatment. Number of treatment visits and change in visual acuity from baseline was plotted for three treatment groups (anti-vascular endothelial growth factor (anti-VEGF), intravitreal dexamethasone, macular laser) for up to 3 years. RESULTS: Mean baseline visual acuity was 57.1/53.1/62.3 letters in the anti-VEGF/dexamethasone/macular laser groups, respectively. This changed to 66.72 (+9.6)/57.6 (+4.5)/63.2 (+0.9) at 12 months. Adequate numbers allowed analysis at 18 months for all groups (66.6 (+9.5)/56.1 (+3.0)/60.8 (-1.5)) and for anti-VEGF at 36 months (68.0, +10.9) Mean number of treatments were 5.1/1.5/1.2 at 12 months, 5.9/1.7/1.2 at 18 months for all three groups and 10.3 at 36 months for anti-VEGF. CONCLUSIONS: Visual acuity improvements were higher and more sustained with anti-VEGF. Higher treatment burden occurred with anti-VEGF but this reduced over 36 months. Patients with better vision at baseline than those in the clinical trials maintained high levels of vision with both anti-VEGF and dexamethasone.
引用
- Gale R, Pikoula M, Lee AY, et al. Real world evidence on 5661 patients treated for macular oedema secondary to branch retinal vein occlusion with intravitreal anti-vascular endothelial growth factor, intravitreal dexamethasone or macular laser. Br J Ophthalmol. 2020. PMID: 32532760. doi:10.1136/bjophthalmol-2020-315836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。